Hansoh Pharmaceutical says Risvutatug rezetecan enters NMPA priority review
Hansoh Pharmaceutical Group said its Risvutatug rezetecan injection has been included in China’s NMPA priority review.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.